Seeking Alpha

TA_Junkie

TA_Junkie
Send Message
View as an RSS Feed
View TA_Junkie's Comments BY TICKER:
Latest  |  Highest rated
  • Level 3 Communications: The Hidden Story [View article]
    Nice work! Based on LVLT chart I also felt it is time to accumulate. Check my instablog for my LVLT chart analysis.
    Aug 1, 2013. 12:05 PM | Likes Like |Link to Comment
  • More on Boston Scientific's (BSX) Q2: EPS doubles analysts' estimates and revenue comes in above the high end of guidance even as sales fall on a Y/Y basis (+2% on a constant currency basis). Revenue growth (as reported) by segment: Interventional Cardiology, -5%; Peripheral Interventions, +2%; Cardiovascular, -4%, Cardiac Rhythm, -3%; Electrophysiology, -3%; Rhythm Management, -3%, Endoscopy, +5%, Urology/ Women's Health, -1%; Neuromodulation, +21%; MedSurg, +6%. Outlook: Q3 and FY EPS of $0.14-0.16 and $0.67-0.71 respectively on sales of $1.7-1.76B next quarter and $7.05-7.17B for the full year. Shares +9% premarket. (PR[View news story]
    One of the most bullish charts among SP500 and a great turn around!
    Jul 25, 2013. 11:59 AM | Likes Like |Link to Comment
  • Changes At Level 3 Communications Could Spell Opportunity [View article]
    Time to accumulate LVLT now. Its weekly chart (see my instablog) looks primed for an upside move and a potential of breaking the $25 resistance.
    Jul 16, 2013. 10:42 AM | Likes Like |Link to Comment
  • T-Mobile USA (TMUS +3.3%) is "Plan B" for SoftBank (SFTBF.PK) if its merger with Sprint (S +0.3%) doesn't go through, says CEO Masayoshi Son. But Son adds he "[plans] to go with Plan A if possible." Reuters reported last week SoftBank is talking with Deutsche Telekom (DTEGY.PK) about buying its 74% stake in T-Mobile USA if the Sprint merger fails thanks to a rival bid from Dish (DISH). For now, Sprint's board (unlike Clearwire's) is spurning Dish. As always, Son isn't lacking for confidence. "I am determined to be No. 1 in the world very soon in my industry ... You are lucky not to be my competitor." [View news story]
    "I am determined to be No. 1 in the world very soon in my industry ... You are lucky not to be my competitor."

    Yeah, go for your plan B, SON! Your new offer provides less capital for S than you have promised in your earlier offer. Taking 3B cash from Sprint and giving it to shareholders while gain 8% more of the company for a 1.5B is a total insult to S share holders intelligence!
    Jun 14, 2013. 07:17 PM | Likes Like |Link to Comment
  • Sprint Is Trading Above Our Fair Value Range [View article]
    Good effort! However your advance analysis model apparently is not working properly and needs to be revised! Perhaps some back-testings of your model with data when S was under $3 and BAC was under $6? will help validate your model! Have you ever done that with your "model"?
    Jun 11, 2013. 12:15 AM | Likes Like |Link to Comment
  • Medtronic And Boston Scientific Are In A Race To Build A Better Pain Device [View article]
    Keep up the good work!
    Jun 9, 2013. 09:40 PM | 1 Like Like |Link to Comment
  • Amgen Inc. Is A Buy For Short Term Investors [View article]
    "The patents will expire completely in the year 2015. After that the company is expecting to face severe competition from the low-cost producers in the United States. "

    Who are these low cost producers for Neupogen and Neulasta? Actually AMGN will become a biosimilar producer for many biologics in a few years!
    Jun 9, 2013. 09:34 PM | Likes Like |Link to Comment
  • Evaluating Johnson & Johnson's Economic Moat [View article]
    LOL, I love opinion/comment such as this! It tells me that BSX still has not been recognized as being undervalued and majority of investors still have bearish views regarding this turnaround stock. Good for me! I will sell to people like you when you start thinking it is "stable" and "up".

    Good luck!
    Jun 2, 2013. 10:40 AM | Likes Like |Link to Comment
  • Wedbush initiates several medical equipment and supply names. Rundown: Boston Scientific (BSX +0.8%), which is "progressing with its turnaround story," is started at Neutral (price target $10) with new product intros serving as "catalysts for higher EPS"; Medtronic (MDT) is started at Neutral (price target $52) and is "an 800-lb. gorilla [facing] growing competition, limited near-term growth, and an overextended valuation"; St. Jude Medical (STJ -0.9%) is started at Outperform (price target $57) as the Durata overhang "is beginning to lose some steam enabling investors to refocus on STJ's healthy pipeline." [View news story]
    Sounds like they finally have realized BSX has more upside potential!
    http://yhoo.it/144LRDW;range=1y;compare=mdt+...
    Jun 1, 2013. 12:57 PM | Likes Like |Link to Comment
  • Evaluating Johnson & Johnson's Economic Moat [View article]
    Fish,
    BSX was in a long term bear trend 5 years ago! It has just bottomed and turned bullish recently. What is the point to look back again? Stock is forward looking. Using your logic noone should buy MDT either since it has been in a trading range for > 12 years...
    Jun 1, 2013. 11:29 AM | Likes Like |Link to Comment
  • Evaluating Johnson & Johnson's Economic Moat [View article]
    Here is the chart from Nov 2012 for BSX and MDT.

    http://yhoo.it/144LRDW;range=20121017,201305...
    May 31, 2013. 10:17 PM | Likes Like |Link to Comment
  • Evaluating Johnson & Johnson's Economic Moat [View article]
    Why don't you consider to buy some BSX too? It is a turnaround story and the stock has outperformed MDT since Nov 2012 and technically it is very strong. MDT also has nice technicals. If it can clear the all time high and breakout of this 12+ year trading range, it is also a strong buy for me. Perhaps owning both is a better option.
    May 31, 2013. 10:13 PM | Likes Like |Link to Comment
  • Zynga: Is The Roller Coaster Back? An Update [View article]
    ZNGA is about to take off. The bull volume/bear volume ration is greater than 3:1 currently ( see my instablog for chart). The correction from the 4.03 high is over. The two hallow red candle (bullish reversal candles) printed low of 3.01 and 3.25 on the daily chart and the 200 day MA has finally finally turned up. I am excited!
    May 25, 2013. 10:26 PM | Likes Like |Link to Comment
  • Technical Analysis Of ZNGA: A Volume Study [View instapost]
    The hollow red candle touched 3.25 is a bullish reversal candle! So it is ready to go! Thanks!
    May 25, 2013. 06:27 PM | Likes Like |Link to Comment
  • 5 Reasons Hydrogenics Could Triple [View article]
    Joe,

    Liked your article a lot, very well written with a lot of info. Congrats!
    The chart looks good too except the avg. volume is so low. It is very dangerous and difficult to trade stock with extreme low daily volume. Stocks with low daily volume can be easily manipulated too.

    Looking forwards to your next article hopefully with stocks have much higher daily volume.

    Keep up the good work!
    May 25, 2013. 05:45 PM | Likes Like |Link to Comment
COMMENTS STATS
26 Comments
7 Likes